☆
Watchlist
Log in
Sign-up
Painchek Ltd (pck) Logo

Painchek Ltd (PCK)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

PCK Chart

Snapshot

PCK's Principal Activity is the development and commercialisation of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -36.63%
vs ASX 200 (1yr) -37.09%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,376 of 2,420
Sector Rank 113 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies VBS / ATH / OSL
EPS -$0.006
DPS $0.00
Book Value Per Share $0.01

Broker Consensus

PCK is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

PainChek Ltd (PCK) is engaged in the development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. PCK is involved in provision of pain management and better medication for residents living with dementia and other communication difficulties. The company has obtained regulatory clearance in Australia and Europe.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sydney NSW 2000
Website www.painchek.com
Registry BoardRoom
Auditor BDO Audit Pty Ltd
Date Listed 1 May 2012

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
07/10/2022 Report (Annual)
27/01/2023 Report (Quarterly)
27/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Cynthia Payne Non-Executive Director Mar 2022

Ms Cynthia Payne

Non-Executive Director

Ms Payne brings 30 years executive leadership experience as well as board and operational experience in residential and home aged care services in Australia. That experience includes over 16 years as CEO for a large private aged care Provider in NSW and before that head of operation manager for a large Not for Profit with home care, residential and retirement living portfolios. She is the founder and Managing Director of Anchor Excellence, a consultancy firm in the aged care services industry in Australia that advises boards and management on operational and compliance best practices. Ms Payne is currently a board advisor to Total Constructions Pty Ltd, a former Director of the Heart Foundation and past Chair of Business Excellence Australia. She is a Certified Chair with The Board Advisory centre.
Ms Sally McDow Company Secretary Jun 2021
Mr Philip Daffas Chief Executive Officer,Managing Director Sep 2016

Mr Philip Daffas

Chief Executive Officer,Managing Director

Mr Daffas is a global business leader and people manager with an international career spanning more than 25 years with leading blue-chip healthcare corporates and novel technology start-up companies. Philip has held senior global business leader positions in Europe, US and Australia. He has been instrumental in building businesses, growing market share and developing extensive high-level customer and industry relationships in each sector on a global basis. Philip's earlier experience was gained in Europe with market leaders such as IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to a Global Marketing role in the Diabetes Care business cased in Mannheim, Germany. In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted in 2000 to the VP Global Marketing role based in Sydney, Australia Other roles in Australia have included General Manager with Roche Diagnostics, Managing Director at Bio-Rad Laboratories and CEO of Applied Physiology, an Australian software start up company in the intensive care monitoring sector.

Mr John Murray Non-Executive Chairman,Non-Executive Director Sep 2016

Mr John Murray

Non-Executive Chairman,Non-Executive Director

Mr Murray has 25 years experience in private equity and venture capital and was a co-founder and Managing Partner of Technology Venture Partners; one of the original and leading venture capital firms in Australia. Mr Murray is a past chairman of the Australian Venture Capital Association. Mr Murray has considerable experience as an investor and a non-executive director of high growth, technologybased companies. He possesses a broad understanding of global trends in technology and its impact on a variety of industries. He is a past Chairman of a private, residential aged care business in Australia. Mr Murray also brings 12 years experience in executive roles in corporate banking, accounting and IT services industries. Mr Murray has been on the Board of a number of successful technology rollouts and exits including online travel play Viator, which was acquired by TripAdvisor for approximately US$200 million in 2014. Mr Murray is a director of UK AIM listed company Seeing Machines Ltd.

Mr Ross Harricks Non-Executive Director Sep 2016

Mr Ross Harricks

Non-Executive Director

Mr Harricks has experience in the commercialisation of medical products which spans over forty years and over three continents. His experience includes the marketing and commercialising of the computed technology scanner (CT or CAT scanner) in Australia, where he headed up the EMI Electronics Group as General Manager. His remit included developing EMI's medical business in this region. In 1983, Mr Harricks joined the Nucleus Group as Group Marketing Executive, and later became President the two Nucleus Group subsidiaries in United States marketing medical equipment and scientific and engineering computing products. In 1989 in the US, Mr Harricks was the CEO of a venture capital-backed start-up company developing specialist scientific and medical lasers. In Australia Mr Harricks has been a director of ResMed Limited and cofounder of AtCor Medical where he completed an Australian initial public offering in 2005 leading the company until 2007. He was a director of VentraCor from 2005 to 2009. Mr Harricks works with Australian medical and technology companies assisting in commercialisation of their products into the US and EU markets. His unique expertise and experience includes strategic advising on the best path to early international market endorsement and adoption, and on providing hands-on help with implementation in the American and European markets.

Mr Adam Stuart Davey Non-Executive Director Sep 2014

Mr Adam Stuart Davey

Non-Executive Director

Mr Davey is a Director of Wealth Management at Canaccord Genuity Patersons Limited. Mr Davey has been involved in growing businesses in both the industrial and mining sector. Mr Davey's expertise spans over 25 years and includes capital raising (both private and public), mergers and acquisition, ASX listings, asset sales and purchases, transaction due diligence and director duties. This has been achieved through holding various roles within different organisations, including chairman, managing director, non-executive director, major shareholder and corporate adviser to the board. Mr Davey is a non-executive director of Ensurance Limited and the Agency Group Australia Ltd.

Iain McAdam Chief Financial Officer N/A

Director Transactions

PCK directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
15/09/21 Adam Davey Issued 396,040 $0.05 $20,000 Issue of securities
15/09/21 Philip Daffas Issued 3,960,396 $0.051 $200,000 Issue of securities
15/09/21 Ross Harricks Issued 396,040 $0.05 $20,000 Issue of securities
15/09/21 John Murray Issued 792,079 $0.051 $40,000 Issue of securities
10/09/20 Adam Davey Issued 206,396 $0.097 $20,000 Issue of securities
10/09/20 Ross Harricks Issued 206,396 $0.097 $20,000 Issue of securities
10/09/20 Philip Daffas Issued 2,063,957 $0.097 $200,000 Issue of securities
10/09/20 John Murray Issued 412,791 $0.097 $40,000 Issue of securities
29/07/20 Adam Davey Buy +93,327 $0.115 $10,733 Conversion of securities
29/07/20 Adam Davey Exercise 93,327 $0.115 $10,733 Conversion of securities
29/07/20 Ross Harricks Buy +93,327 $0.214 $20,000 Conversion of securities
29/07/20 Ross Harricks Exercise 93,327 $0.214 $20,000 Conversion of securities
29/07/20 John Murray Buy +186,654 $0.131 $24,465 Conversion of securities
29/07/20 John Murray Exercise 186,654 $0.131 $24,465 Conversion of securities
13/12/19 Ross Harricks Issued 93,327 $0.214 $20,000 Issue of securities
13/12/19 Philip Daffas Issued 933,270 $0.214 $200,000 Issue of securities
13/12/19 John Murray Issued 186,654 $0.214 $40,000 Issue of securities
13/12/19 Adam Davey Issued 93,327 $0.214 $20,000 Issue of securities
27/11/19 Ross Harricks Sell +6,149,874 $0.20 ($1,229,975) On-market trade
27/11/19 John Murray Sell +12,299,749 $0.20 ($2,459,950) On-market trade
27/11/19 Adam Davey Sell +6,149,874 $0.20 ($1,229,975) On-market trade
27/11/19 Philip Daffas Sell +20,499,581 $0.20 ($4,099,916) On-market trade
22/11/19 Philip Daffas Exercise 40,999,162 $0.02 $819,983 Exercise of options
22/11/19 Adam Davey Buy +12,299,748 $0.02 $245,995 Exercise of options
22/11/19 Ross Harricks Buy +12,299,748 $0.02 $245,995 Exercise of options
22/11/19 Adam Davey Exercise 12,299,748 $0.02 $245,995 Exercise of options
22/11/19 John Murray Buy +24,599,497 $0.02 $491,990 Exercise of options
22/11/19 Ross Harricks Exercise 12,299,748 $0.02 $245,995 Exercise of options
22/11/19 John Murray Exercise 24,599,497 $0.02 $491,990 Exercise of options
22/11/19 Philip Daffas Buy +40,999,162 $0.02 $819,983 Exercise of options
Show All

Director Interests

The current holdings of PCK directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Cynthia Payne 30/03/2022 0 N/A N/A N/A
Ross Harricks 30/06/2021 6,243,201 N/A N/A N/A
John Murray 30/06/2021 186,654 12,299,748 N/A N/A
Philip Daffas 30/06/2021 20,499,581 N/A N/A N/A
Adam Davey 30/06/2021 3,634,091 6,149,874 N/A N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Sep 26, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Peters Investments Pty Ltd 113,000,000 9.98%
HSBC Custody Nominees (Australia) Limited 41,338,803 3.65%
J&E Consulting Pty Ltd 37,003,125 3.27%
Dr Kreshnik Hoti 37,003,125 3.27%
Mr Mustafa Abdul Wahed Atee 37,003,125 3.27%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 26,033,862 2.30%
Mr Philip Daffas 20,499,581 1.81%
Thornbury Nominees Pty Ltd <The Stevens Family S/F A/C> 15,050,000 1.33%
G & G Chilcott Pty Ltd <G & G Chilcott S/F A/C> 13,927,169 1.23%
Mr Robert Anthony Healy 12,857,143 1.14%
Nanjop Pty Ltd <The Murring Family A/C> 12,299,748 1.09%
Mr Allan Graham Jenzen & Mrs Elizabeth Jenzen <Ag & E Jenzen P/L No2 Sf A/C> 12,277,974 1.08%
Citicorp Nominees Pty Limited 11,890,945 1.05%
Capper Superannuation Pty Ltd <Capper Super Fund A/C> 11,674,331 1.03%
Xtreme Nominees Pty Ltd <The Investment Unit A/C> 11,654,791 1.03%
Mr Robert Anthony Healy i 11,000,000 0.97%
Ms Eloise Kathleen Jennings & Mr Andrew John Hopkins <Jennings Hopkins Discret A/C> 10,599,791 0.94%
Ms Eloise Kathleen Jennings & Mr Andrew John Hopkins <Jennings Hopkins S/F A/C> 10,486,709 0.93%
Bradan Investments Pty Limited <Mcguirk Family A/C> 10,000,000 0.88%
Mr Craig Robert Williamson 9,433,000 0.83%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 86 505 873 2,484 1,027 4,975

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Peters Investments Pty Ltd 26/09/2021 113,000,000 9.98

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.059 30 June
2020 $0.115 30 June
2019 $0.20 28 June
2018 $0.056 29 June
PCK Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.